Hemogenyx Pharmaceuticals Share Discussion Threads

[davevt] 09/2/2020 01:08

Sorry John, I wrote it wrong, I meant she owns more shares that are worth more than yours 😅

[elpirata] 08/2/2020 20:17

interesting times ahead with Masthercell being bought out for $315m - recall the Hemo>Immugenyx/Orgenesis>Masthercell Belgium link?

The company is being backed by three of its partners — Theracell, Hemogenyx, and Serpin — to expand cellular therapy development in the Walloon region of Belgium.



Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform

SOMERSET, N.J. & GOSSELIES, Belgium--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ:ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.

“MaSTherCell extends our leadership position in the biotech industry, complements our leading gene therapy offering, and allows us to deliver comprehensive development, manufacturing, analytical, fill-finish, and clinical supply solutions for innovators across the large molecule space,” said John Chiminski, Catalent’s Chair & Chief Executive Officer. “Both autologous and allogeneic cell therapies provide important new treatment options, with a rising number expected to gain regulatory approval over the coming years. Catalent is well-positioned to combine MaSTherCell’s expert teams and capabilities with our extensive resources and experience in scaling new platforms, and to help MaSTherCell build-out its development and commercial manufacturing capabilities.”

Founded in 2011, MaSTherCell has a 25,000 square-foot facility in Gosselies, Belgium providing clinical services, and construction is in progress on a dedicated 60,000 square-foot adjacent commercial-scale production and fill-finish facility, which is scheduled to open in the fall of 2021 and ultimately add over 250 new jobs to the current team of over 240. Its 32,000 square-foot U.S. facility in Houston, Texas, upon completion of validation activities, will focus on development-scale projects and will employ a team of over 50 experts before the end of the year. MaSTherCell has a growing customer base and offers a unique portfolio of capabilities and technologies that include the development and manufacture of autologous and allogeneic cell therapies, as well as a variety of related analytical services. Its experience includes therapies based on chimeric antibody receptor-engineered T cells (CAR-T), T cell receptors (TCR), tumor-infiltrating lymphocytes (TIL), and mesenchymal stem cells (MSC).

Darren Head, MaSTherCell’s Chief Executive Officer, commented, “MaSTherCell has built comprehensive capabilities to address the complexities of cell therapy production. Like Catalent, our experience has taught us the importance of technology selection, advanced know-how, and quality and regulatory expertise for successful cell therapy programs that are aimed at producing life-altering treatments. We are excited to join the industry-leading team at Catalent and work together to scale-up our business. This combination will strengthen our service offering to our customers and, in the end, benefit patients who need innovative life-saving therapies. Catalent’s backing will position MaSTherCell for growth and enhance Catalent’s existing presence in Belgium.”

Vered Caplan, Chief Executive Officer of Orgenesis, stated, “We are very proud of the developments and accomplishments at MaSTherCell, which has become a best-in-class contract development and manufacturing organization (CDMO) servicing many of the leading cell and gene therapy companies. Since we completed our acquisition of MaSTherCell in 2015, the business has grown along with this burgeoning industry. With Catalent’s expertise and resources, we believe MaSTherCell will be well positioned to continue on its current trajectory in order to meet the evolving needs of the industry.”

Noah Rhodes, Managing Director at Great Point Partners, commented, “We identified MaSTherCell as the leading provider of development and manufacturing services to cell and gene therapy companies, and have enjoyed watching the company and its team continue to flourish. We cannot think of a better partner for MaSTherCell than Catalent, as the combined company will be a leading vertically-integrated provider able to serve customers and patients on a global basis.”

Upon completion of the transaction, which is expected in the current, third quarter of Catalent’s 2020 fiscal year and is subject to customary closing conditions, MaSTherCell’s 240 talented employees, including its outstanding leadership team, will become part of the Catalent Biologics business.

The acquisition is an all-cash transaction, which Catalent expects to finance with either a partial drawn down of its revolving credit facility or the proceeds from future capital-raising activity. As part these activities, Catalent has obtained $200 million of committed financing, subject to customary conditions, from JPMorgan Chase Bank N.A. It should be noted, however, that the agreement governing the acquisition is not contingent on any financing activity. Catalent intends to file a Current Report on Form 8-K with the Securities and Exchange Commission, which will have further details concerning the acquisition and the committed financing.

About Catalent, Inc.

Catalent, Inc. [NYSE: CTLT] is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

[delano1967] 08/2/2020 19:10

Still feeding the cats...

[davevt] 08/2/2020 16:23

John, you're so boring. She is invested more than you are, and at least interacts with the company.

You say 'I' shouldn't be here because I'm not currently invested, but she has more right than you do 😅 so who are you to tell another investor what they can or can't do or say.

We are all fed up of your stupid posts.

You're a nobody! 😅

[davevt] 08/2/2020 16:21

Yes, but you should have exited. Always play the 30 percent rule. You're only up when you sell, as now you're at a loss again.

[marie1980] 08/2/2020 15:05

When you invest in penny shares, be prepared that 90 percent of the companies fail, or will place many times in 3 years so you could have always bought in cheaper


- Agree Dave. In fact, hemo even with pre clinical trial was a good trade. I mean I understood that with penny pharma shares, p3 success doesn’t matter as far as you know when to exit. I learned that one can made mistake while entering into any share but when to exit is a key.

Like it was a fortunate or me when I put like £9,000 just few days back here at 1.9 and then RNS came and hemo jumped to 2.5 which is 30% of a rise for me if I’d exited.

Okay still learning but talking about IMM, I’m there for minimum 2 years and once FDA agreed protocol with IMM for p3 then co confident of a steady rise.

[davevt] 08/2/2020 13:55

Makes me laugh how people are discussing with (fake) excitement about 'public relations' with this company, and the videos etc.

Think about this, and it applies to any floated company like this, not just hemo.

They are a medical company, in the medical world, and do not deal or sell to the public. In fact what the public feel or know is totally irrelevant, the companies customers are the trade / the industry etc.

So the only reason floated companies are doing stuff 'for the public', (as I'm sure you'd agree, some potential big pharma company won't be learning of this one through a little YouTube video) is so they can encourage the public to buy shares.

Floated companies don't really care about your share price, other than directors own stock being devalued, and so they can boost share prices so they can place at higher amounts. and if the directors have share options, they can sell them once they hit a certain target.

It's ramping, simple as that.

[davevt] 08/2/2020 13:47

When you invest in penny shares, be prepared that 90 percent of the companies fail, or will place many times in 3 years so you could have always bought in cheaper.

[johntopdog] 07/2/2020 21:36

Why dont you post details of your share trades in hemo then Dave, seeing as you have made so much money....I dont know what's funnier, you trading this share or having a girlfriend....both are fantasy!!...you are the poster we all laugh at on here...

[davevt] 07/2/2020 20:52

Correct,

1.. no one knows the bottom, that's why you don't throw 60 grand at it..

2. You're not up 20 percent because of the spread, and you're only up if you sell..

..which leads onto point..3..

3..you wouldn't be able to sell 60 grands worth even if you wanted to.

To get rid of 60 grand you need to drip feed sells on the way up and way down, steady rises and falls. Spikes will be no good to you,

[purple11] 07/2/2020 20:34

willy waving

[davevt] 07/2/2020 19:13

Marie, you're nuts. You're invested in a share that if you look at the 3 month chart is on a constant downtrend. It hasn't even hit the bottom yet.

[marie1980] 07/2/2020 14:56

With HEMO,

My investment in IMM is now close to £70,000




I'm out of Sheild.

[purple11] 07/2/2020 14:23

try leaving the bedsit every now and again.it may help.atb

[davevt] 07/2/2020 12:47

Where's all the excitement gone from yesterday lads?